ArticleEye (London, England)2014
Evaluation of pain during intravitreal Ozurdex injections vs. intravitreal bevacizumab injections.
Article in Eye (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Quadrant-Specific Pain in Intravitreal Injection: A Systematic Review and Meta-analysis.Ophthalmology and therapy · 2026Review
- Intravitreal OZURDEX vs. Intravitreal Bevacizumab for Diabetic Macular Edema: A Comprehensive Review.Cureus · 2024Review
- Potential Risk Factors for Ocular Pain in Patients Undergoing Multiple Intravitreal Injections of Anti-Vascular Endothelial Growth Factor.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Cooling Anesthesia for Intravitreal Injections - A Review.Clinical ophthalmology (Auckland, N.Z.) · 2023Review
- Long-term efficacy of dexamethasone intravitreal implant in the treatment of Vogt-Koyanagi-Harada disease relapsing posterior uveitis.Indian journal of ophthalmology · 2022Article
- An intravitreal implant injection method for sustained drug delivery into mouse eyes.Cell reports methods · 2021Article
- Feelings, preoperative anxiety, and need for information in patients undergoing intravitreal injections.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020Observational
- Extended release of dexamethasone from oleogel based rods.Journal of colloid and interface science · 2019Article
- Recent advances in intraocular sustained-release drug delivery devices.Drug discovery today · 2019Review
- Factors Associated with Pain Following Intravitreal Injections.Korean journal of ophthalmology : KJO · 2018Article
- Patient pain during intravitreal injections under topical anesthesia: a systematic review.International journal of retina and vitreous · 2017Article
- Strategies for Improving Patient Comfort During Intravitreal Injections: Results from a Survey-Based Study.Ophthalmology and therapy · 2016Article
- Dexamethasone intravitreal implant in the treatment of diabetic macular edema.Clinical ophthalmology (Auckland, N.Z.) · 2015Review
- Evaluation effectiveness of 0.1% nepafenac on injection-related pain in patients undergoing intravitreal Ozurdex injection.Therapeutic advances in ophthalmologyArticle
- Evaluation of pain scores during intravitreal injection in systemic conditions and in conjunction with medications.Therapeutic advances in ophthalmologyArticle
- Assessment of Patient Pain Experience During Intravitreal Ranibizumab and Aflibercept Injection.Middle East African journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose was to evaluate the pain associated with intravitreal Ozurdex injections, and to compare it with that associated with intravitreal bevacizumab injections.
methodsThe study included 57 eyes of 57 patients who received an intravitreal Ozurdex injection at our institution. Pain was measured by the visual analog scale (VAS). Additional parameters recorded included age, sex, indication for the injection, number of previous Ozurdex injections in the study eye, presence of diabetes mellitus, and lens status. Data were compared with a 2 : 1 sex- and age-matched control group of 114 patients who received intravitreal bevacizumab injections.
resultsIndications for injection included diabetic macular edema (40.4%) and macular edema secondary to central and branch retinal vein occlusion (28% and 31.6%, respectively). Pain scores on the VAS ranged from 0 to 90, with a mean of 20.8±20.3. There was no significant difference in pain between Ozurdex and bevacizumab injections. Pseudophakia was correlated with increased pain in Ozurdex injections.
conclusionsThis is the first series evaluating the pain associated with intravitreal Ozurdex injections. Despite a larger needle gauge and tunneled injection technique, intravitreal injection of Ozurdex is not associated with increased pain compared with bevacizumab. This finding may be a potential advantage for Ozurdex, and may serve to improve patient compliance with future long-term treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.